Inovio Pharmaceuticals (INO) Is Today's Dead Cat Bounce Stock
Trade-Ideas LLC identified Inovio Pharmaceuticals ( INO) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Inovio Pharmaceuticals as such a stock due to the following factors:
- INO has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $19.2 million.
- INO has traded 930,295 shares today.
- INO is up 3.6% today.
- INO was down 6.3% yesterday.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in INO with the Ticky from Trade-Ideas. See the FREE profile for INO NOW at Trade-Ideas
More details on INO: Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. Currently there are 5 analysts that rate Inovio Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Inovio Pharmaceuticals has been 1.9 million shares per day over the past 30 days. Inovio has a market cap of $789.4 million and is part of the health care sector and drugs industry. The stock has a beta of 2.91 and a short float of 17.4% with 6.61 days to cover. Shares are up 66.4% year-to-date as of the close of trading on Thursday.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
Analysis:
rates Inovio Pharmaceuticals as a
. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income and feeble growth in its earnings per share. Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 142.2% when compared to the same quarter one year ago, falling from -$7.41 million to -$17.95 million.
- INOVIO PHARMACEUTICALS INC has experienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has reported somewhat volatile earnings recently. We feel it is likely to report a decline in earnings in the coming year. During the past fiscal year, INOVIO PHARMACEUTICALS INC continued to lose money by earning -$0.45 versus -$0.63 in the prior year. For the next year, the market is expecting a contraction of 93.3% in earnings (-$0.87 versus -$0.45).
- The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, INOVIO PHARMACEUTICALS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Looking at where the stock is today compared to one year ago, we find that it is higher, and it has outperformed the rise in the S&P 500 over the same period, despite the company's weak earnings results. Turning our attention to the future direction of the stock, we do not believe this stock offers ample reward opportunity to compensate for the risks, despite the fact that it rose over the past year.
- Net operating cash flow has increased to -$6.77 million or 16.11% when compared to the same quarter last year. In addition, INOVIO PHARMACEUTICALS INC has also vastly surpassed the industry average cash flow growth rate of -49.98%.
- You can view the full Inovio Pharmaceuticals Ratings Report.
EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.
